Rheumatologists Lead Biosimilar Uptake with Value-Based Pathways

By Colin C. Edgerton, M.D. Biosimilar Adoption Falters Rheumatologists hoped that biosimilars would reduce the costs of treating diseases such as rheumatoid arthritis (RA), and thereby increase access to these life altering medications for our patients. The recent Forbes article, “Biosimilars Continue to Exhibit Market Failure” confirms what we as rheumatologists are observing, that biosimilars …

Rheumatologists Lead Biosimilar Uptake with Value-Based Pathways Read More »